论文部分内容阅读
目的:评价甘精胰岛素联用西格列汀治疗口服降糖药控制不佳的老年2型糖尿病的有效性及安全性。方法:采用随机、开放,门冬胰岛素30平行对照的研究方法,将98例60岁以上口服降糖药物控制不佳的2型糖尿病患者随机分成甘精胰岛素联用西格列汀组(观察组)52例和门冬胰岛素30特充组(对照组)46例,根据血糖情况调整用药剂量,治疗12周后比较两组的空腹血糖(FBG)、餐后2h血糖(2hPBG)、糖化血红蛋白(HbA1c)、低血糖发生率及体质指数(BMI)。结果:观察组FBG和低血糖发生率均低于对照组(P<0.05);2hPBG、HbA1c和BMI等指标比较两组差异无统计学意义(P>0.05)。结论:甘精胰岛素与西格列汀联用对口服降糖药控制不佳老年2型糖尿病患者是一种安全、有效且方便的治疗方案,低血糖发生率低,通过糖尿病教育的实施,将是一种很好的治疗方案。
OBJECTIVE: To evaluate the efficacy and safety of glargine plus sitagliptin in the treatment of elderly type 2 diabetes with poorly controlled oral hypoglycemic agents. Methods: A total of 98 patients with type 2 diabetes who were overdosed with oral hypoglycemic drugs over 60 years old were randomly divided into glargine and sitagliptin group (observation group, randomized, open and insulin aspart 30 parallel control study) ) And insulin aspart 30 superficies group (control group), 46 cases were treated with insulin as control group, the dosage of FBG was adjusted according to the blood glucose level. After 12 weeks of treatment, the fasting blood glucose (FBG), 2h postprandial blood glucose (2hPBG), HbA1c HbA1c), the incidence of hypoglycemia and body mass index (BMI). Results: The incidences of FBG and hypoglycemia in the observation group were lower than those in the control group (P <0.05). There was no significant difference between the two groups in the indexes of 2h PBG, HbA1c and BMI (P> 0.05). CONCLUSIONS: Combination of glargine and sitagliptin is a safe, effective and convenient treatment for elderly patients with type 2 diabetes with poorly controlled oral hypoglycemic agents. The incidence of hypoglycaemia is low. Through the implementation of diabetes education, Is a good treatment.